Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Agilent Technologies, Baylor College of Medicine open Center of Excellence

Monday, December 8, 2014 01:06 PM

Agilent Technologies, headquartered in Santa Clara, Calif., and Houston, Texas-based Baylor College of Medicine have opened the Agilent Technologies Mass Spectrometry Center of Excellence as part of the Alkek Center for Molecular Discovery and the Baylor College of Medicine Core Laboratory in the college's department of molecular and cellular biology.

More... »


Aldeyra Therapeutics, National Organization for Rare Disorders collaborate

Monday, December 8, 2014 01:04 PM

Aldeyra Therapeutics, a Massachusetts-based biotechnology company focused on the development of products to treat diseases related to free aldehydes, is collaborating with the National Organization for Rare Disorders (NORD), a U.S. nonprofit organization dedicated to helping people with rare diseases.

More... »


The Study Coordinator-CRA relationship

Monday, December 8, 2014 08:00 AM

The Study Coordinator (SC)-CRA relationship is pivotal to site success.

More... »

Proposed NIH policy calls for a single IRB to accelerate multi-centered trials and reduce redundancy

Friday, December 5, 2014 12:40 PM

The National Institutes of Health (NIH) officially has backed a draft policy calling for a single IRB for multi-site reviews of NIH-supported clinical trials—a streamlined strategy it says will accelerate trials without compromising safety.

More... »

Pharmacyclics launches informCLL registry for CLL patients

Friday, December 5, 2014 12:37 PM

Pharmacyclics, a Sunnyvale, Calif.-based biopharmaceutical company, has launched informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how Imbruvica (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). Imbruvica is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, and the registry is a joint effort between the companies. Registry enrollment will begin in the first half of 2015.

More... »

INC Research expands relationship with Society for Clinical Research Sites

Friday, December 5, 2014 12:36 PM

INC Research Holdings, a global phase I-IV CRO headquartered in Raleigh, N.C., has announced an expanded partnership with the Society for Clinical Research Sites (SCRS), an Ellicott City, Md.-based global trade organization, to become the society’s first Circle of Sustainability Sponsor, reinforcing the INC’s commitment to fostering strong site relationships globally.

More... »

Thomson Reuters, Linguamatics launch solution to advance clinical R&D

Friday, December 5, 2014 12:34 PM

The Intellectual Property and Science business of Thomson Reuters, a provider of intelligent information for businesses and professionals, is collaborating with Linguamatics, a U.K.-based provider of text analytics software, to advance pharmaceutical clinical trial R&D with the launch of Cortellis Informatics Clinical Text Analytics for I2E.

More... »

ALS Association, Muscular Dystrophy Association partner

Friday, December 5, 2014 12:33 PM

The ALS Association, a national nonprofit based in Wash. D.C., and the Muscular Dystrophy Association (MDA), a Chicago-based nonprofit health agency, have joined forces to fund a research project aimed at finding a potential therapy for amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. Both nonprofits are focused on finding treatments and cures for ALS and providing services for those affected with the debilitating, fatal disease.  

More... »

Merck’s EngageZone receives IDG’s CSO Security Award

Thursday, December 4, 2014 02:22 PM

EngageZone has been named an honoree of a 2015 CSO50 Award from IDG's CSO. This prestigious honor is awarded to a select group of organizations with security projects that have created outstanding business value and thought leadership for their companies.

More... »

FDA approves Blincyto (Blinatumomab) for leukemia

Thursday, December 4, 2014 02:20 PM

The FDA has granted approval of Amgen’s Blincyto (blinatumomab) for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs